These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 15373065)
1. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
3. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]
4. Drug interactions. Kaletra and atazanavir. TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919 [No Abstract] [Full Text] [Related]
5. [New data on atazanavir/r]]. MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887 [No Abstract] [Full Text] [Related]
6. [New treatment options for HIV-infected patients]. Wehr A Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468 [No Abstract] [Full Text] [Related]
7. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
12. A king in the CASTLE? Optimum initial HIV protease inhibitor. Torti C; Frank I Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849 [No Abstract] [Full Text] [Related]
13. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Chetchotisakd P Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222 [TBL] [Abstract][Full Text] [Related]
14. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981 [No Abstract] [Full Text] [Related]
15. 96-week CASTLE data show similar efficacy results. AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840 [No Abstract] [Full Text] [Related]
18. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
20. [Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():14-6. PubMed ID: 15373035 [No Abstract] [Full Text] [Related] [Next] [New Search]